诺尔康人工耳蜗技术在中国的应用与前景  

The Application and the Future：Nurotron Cochlear Technology in China

作　　者：杨仕明[1] 李佳楠[1] 

机构地区：[1]解放军总医院耳鼻咽喉头颈外科,北京100853

出　　处：《中国听力语言康复科学杂志》2015年第2期84-87,共4页Chinese Scientific Journal of Hearing and Speech Rehabilitation

摘　　要：人工耳蜗是目前应用最成功的神经植入假体技术，世界范围内已有30余万重度以上听障患者通过人工耳蜗植入重获听觉功能。但是相对于庞大的耳聋人口基数，仅有少部分候选人群获得了人工耳蜗植入的机会，人工耳蜗价格昂贵是原因之一。30年来中国也一直在研发人工耳蜗产品，但一直未广泛用于临床。直到近年一种新型的26电极诺尔康人工耳蜗研发成功，在全国5家医院完成了临床验证并取得较满意效果，2011年通过了中国食品药品监督管理局（CFDA）审批，2012年获得了欧盟CE认证。诺尔康人工耳蜗的成功研发和应用，降低了人工耳蜗植入的费用，并有望推动人工耳蜗在世界其它国家的广泛应用。本文将介绍诺尔康人工耳蜗装置的研发背景、产品特点、临床验证及应用前景等，从侧面展现中国人工耳蜗发展的脉络与历程。未来人工耳蜗产品的发展方向是更加小巧、人性化，进一步融合相关领域的新技术，随着电子技术的发展和生物治疗技术的新发现，最终可能实现植入体全植入和听觉通路全覆盖。Cochlear implants （CIs） have been widely acknowledged that the most successful neural prosthesis used in deafness. More than 300,000 deaf patients in the world received this kind of prosthesis. Although the huge number of deaf people, the amount of CI beneficiaries is still limited. It’s still too expensive to afford for most of the candidates. During the past 30 years, there is nonstop exploration in cochlear technology development in China. A 26-electrod cochlear implant Nurotron was devised and conduced in recent years. It has received China’s Food and Drug Administration （CFDA） approval in 2011 and European Commission （CE） marking in 2012. It’s helpful to lower the cost of CI in China. And it may also be widely used in other countries in the future. This comment will introduce the background of Nurotron, device specification, clinical test, and future prospects. It also reflects the history of CI evolution in China. The future tendency of CI device is more miniaturization and smarter, even move forward to full implantation, combined with new technology and new material.

关 键 词：诺尔康人工耳蜗 产品性能 评估 应用前景 

分 类 号：R764.43[医药卫生—耳鼻咽喉科]